The emergence of medications like copyright and Semaglutide signifies a remarkable shift in how we treat metabolic disorders. These groundbreaking therapies belong to a class known as GLP-1 action agonists, which duplicate the effects of a natural hormone that manages glucose levels and hunger. Originally, developed for diabetes, their effectivenes